J. Guégan

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Jean-philippe Guégan, J-p Guegan, Jean‐philippe Guegan, Jean‐philippe Guégan, J. P. Guegan, J P Guégan, J-p. Guegan, Jean Philippe Guégan, Jean Philippe Guegan, Jean-philippe Guegan
Publication record
89 papers · 1,900 citations · H-index 22

PAPERS

Adenosine A2B Receptor Promotes Tumor Progression and Metastases in Undifferentiated Pleomorphic Sarcoma.
20260 citationsauthor #2
Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis
20257 citationsauthor #2
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab
20257 citationsauthor #2
Evaluation of the combination of regorafenib + avelumab in patients with non-small cell lung cancer without oncogenic addiction: The phase II REGOMUNE study.
20250 citationsauthor #3
Abstract 5256: Tertiary Lymphoid Structures as Predictors of Immune Checkpoint Inhibitor Efficacy in NSCLC and the Development of an Ex Vivo Model for Precision Medicine
20250 citationsauthor #1
Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures
202530 citationsauthor #2
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside.
202521 citationsauthor #2
Biological determinants of immune exclusion in non-small cell lung cancer: An analysis of the precision medicine BIP study.
20250 citationsauthor #1
Abstract CT129: Immunity induction with atezolizumab, EIK1001, and radiotherapy in virus-associated tumors: Results of the AGADIR Trial
20250 citationsauthor #13
Immune control of functional memory CD8 T cells in normal-appearing vitiligo skin
20250 citationsauthor #13
Abstract 2419: Impact of immune contexture on immunotherapy response in NSCLC: insights from multiplex IHC and machine learning-based phenotyping
20250 citationsauthor #1
457 GABA promotes resistance to immunotherapy of patients with TLS-positive tumours
20250 citationsauthor #14
CCR8 positive Tregs and their correlation with immunotherapy response in advanced non-small cell lung cancer (NSCLC).
20250 citationsauthor #1
Abstract 7471: Cancer-associated fibroblasts drive T cell infiltration and resistance to immunotherapy in non-small cell lung cancer with mature tertiary lymphoid structures
20243 citationsauthor #2
Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response
202421 citationsauthor #1
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-VEGFR targeted therapy: A Phase 2 Trial of Regorafenib combined with avelumab.
20241 citationsauthor #2
Deciphering the correlation between metabolic activity through 18F-FDG-PET/CT and immune landscape in soft-tissue sarcomas: an insight from the NEOSARCOMICS study
20240 citationsauthor #4
Abstract 7392: Machine learning-based identification of H&E-derived morphologic features associated with CD8+ T cell immune exclusion
20240 citationsauthor #4
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide
202432 citationsauthor #2
1378 Stromal collagen features from H&E-stained whole slide images are associated with lymphocyte infiltration and survival following checkpoint inhibition in patients with non-small cell lung cancer
20240 citationsauthor #11
Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics
202417 citationsauthor #2
Predictive value of tumor microenvironment on pathologic response to neoadjuvant chemotherapy in patients with undifferentiated pleomorphic sarcomas
20247 citationsauthor #1
574 Exclusion of CD8 T cells from tumor epithelium is associated with worse immune checkpoint blockade (ICB) therapy response and survival in non-small cell lung cancer (NSCLC)
20240 citationsauthor #4
Abstract CT033: Avelumab combined with regorafenib in solid tumors with tertiary lymphoid structures: A phase 2 REGOMUNE trial cohort
20244 citationsauthor #4
Abstract 2916: Discoidin domain receptor 1 (DDR1) expression is associated with degree of immune exclusion across epithelial tumors
20240 citationsauthor #5
Correlation of immune phenotypes derived from H&E-stained whole slide images with prognosis and response to checkpoint inhibitors in NSCLC.
20240 citationsauthor #12
TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.
20231 citationsauthor #3
Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer
202315 citationsauthor #11
1519 Avelumab combined with regorafenib in solid tumors with tertiary lymphoid structures: a phase 2 REGOMUNE trial cohort
20230 citationsauthor #3
Targeting EZH2 to overcome the resistance to immunotherapy in microsatellite stable colorectal cancer: Results from the CAIRE study.
20234 citationsauthor #4
Abstract 2108: High prevalence of immune exclusion in cancer as determined by pathologist assessment and image analysis
20230 citationsauthor #5
Antitumor Effects of PRMT5 Inhibition in Sarcomas
20233 citationsauthor #3
1521 Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer: a joint analysis of the REGOMUNE and REGONIVO studies
20230 citationsauthor #1
1287 Comparison of multiplex immunofluorescence and H&E-based approaches for characterization of the tumor microenvironment
20231 citationsauthor #5
782-G The correlation of tumor immune microenvironment with response to neoadjuvant chemotherapy response in undifferentiated pleiomorphic sarcomas: an analysis of the NEOSARCOMICS study
20230 citationsauthor #2
1920MO Regomune: A phase II study of regorafenib + avelumab in solid tumors - Results of the advanced or metastatic gastrointestinal stromal tumors (mGIST) cohort
20232 citationsauthor #3
Abstract 4705: Profiling of immune cell components and soluble factors in ovarian cancer ascites highlights impaired immune environment
20230 citationsauthor #4
Abstract 6767: Cancer-associated fibroblasts promote T-cell exclusion and resistance to immunotherapy in non-small cell lung cancer with tertiary lymphoid structures
20232 citationsauthor #2
TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non–Small Cell Lung Cancer
202332 citationsauthor #13
Abstract 4341: Indoleamine 2,3-dioxygenase 1 is highly expressed in tertiary lymphoid structures and associated with improved outcome in patients with advanced non-small cell lung cancer treated with anti-PD1/PDL1 inhibitors
20230 citationsauthor #1
Abstract LB224: STC-1010 a new therapeutic vaccine promotes tumor cell death
20230 citationsauthor #4
1497 The epithelium-stroma interface serves as a barrier to immune cell infiltration across tumor immune phenotypes in epithelial cancers
20230 citationsauthor #5
First in class TLR7/8 agonist BDB001 combined with atezolizumab and stereotactic body radiation therapy in patients with advanced pancreatic adenocarcinoma: Results from the AGADIR study.
20236 citationsauthor #7
Abstract 1251: Low plasma Arginine level is associated with resistance to immune checkpoint blockers in patients with advanced cancer
20221 citationsauthor #1
Abstract 3937: PRMT5 inhibition suppress soft tissue sarcomas tumorigenicity through the regulation of glucose metabolism
20220 citationsauthor #6
Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer
202210 citationsauthor #4
Circulating L-Arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.
202258 citationsauthor #2
REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the oesophageal or gastric carcinoma (OGC) cohort.
20223 citationsauthor #4
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort
2022204 citationsauthor #11
Abstract 622: Development and characterization of a novel anti-PD1 resistant sarcoma mouse model
20220 citationsauthor #2
141 Indoleamine 2,3 dioxygenase expression predicts response to immune checkpoint blockers in advanced non-small cell lung cancer
20220 citationsauthor #3
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies
2022122 citationsauthor #2
Signaling by the tyrosine kinase Yes promotes liver cancer development
202220 citationsauthor #1
1426 Comprehensive analysis of a novel anti-PDL1 resistant sarcoma mouse model
20220 citationsauthor #2
Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.
202242 citationsauthor #3
Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
202293 citationsauthor #2
Abstract 2527: Ovarian cancer ascites display altered immune environment featured by enhanced soluble factors and suppressive cellular context
20220 citationsauthor #4
Abstract 2578: High regulatory T cells infiltrate within tertiary lymphoid structure restricts response to immune checkpoint blockers in sarcomas
20221 citationsauthor #2
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
202241 citationsauthor #4
Impact of acetaminophen on the efficacy of immunotherapy in cancer patients.
202238 citationsauthor #3
Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
202216 citationsauthor #3
Identification of super-exhausted T cells: A novel population predictive of response to immunotherapy.
20222 citationsauthor #2
REGOMUNE: Phase II study of regorafenib plus avelumab in solid tumors—Results of the gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) cohort.
20222 citationsauthor #3
CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism
202119 citationsauthor #1
CD95 expression in triple negative breast cancer blocks induction of an inflammatory state through differential regulation of NF-κB Signaling
20211 citationsauthor #1
Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance.
202164 citationsauthor #3
PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.
202119 citationsauthor #10
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
2021429 citationsauthor #3
Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort.
20215 citationsauthor #3
Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial
202190 citationsauthor #3
Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study.
202122 citationsauthor #10
CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells
202114 citationsauthor #2
Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis
202144 citationsauthor #6
Tumor expressed CD95 causes suppression of anti-tumor activity of NK cells in a model of triple negative breast cancer
20212 citationsauthor #2
REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort.
202031 citationsauthor #3
Abstract 934: “GPCR-ome” modulation upon PD1 / PDL1 axis blockade
20200 citationsauthor #4
CD95/Fas and metastatic disease: What does not kill you makes you stronger.
202039 citationsauthor #1
Probing the side chain tolerance for inhibitors of the CD95/PLCγ1 interaction.
20192 citationsauthor #2
HIV protease inhibitors and autoimmunity: An odd, but promising idea.
20190 citationsauthor #3
Synthesis of peptidomimetics and chemo-biological tools for CD95/PLCγ1 interaction analysis.
20192 citationsauthor #2
Disrupting the CD95–PLCγ1 interaction prevents Th17-driven inflammation
201828 citationsauthor #2
Nonapoptotic functions of Fas/CD95 in the immune response
201872 citationsauthor #1
Non-apoptotic functions of Fas / CD 95 in the immune response
20176 citationsauthor #1
MEK1/2 Overactivation Can Promote Growth Arrest by Mediating ERK1/2‐Dependent Phosphorylation of p70S6K
201422 citationsauthor #1
The MAPK MEK 1 / 2-ERK 1 / 2 Pathway and Its Implication in Hepatocyte Cell Cycle Control
20133 citationsauthor #1
MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells.
201352 citationsauthor #1
The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control
201260 citationsauthor #1
The complexity of ERK1 and ERK2 MAPKs in multiple hepatocyte fate responses
201220 citationsauthor #3
2.27 Differential Gene Expression and Secretory Profiles of Nurse-like Cells Specifically Derived from Chronic Lymphocytic Leukemia Help Decipher New Pathways to Pathogenesis
20110 citationsauthor #4

TIMELINE

2011 0 citations

2012 80 citations

2013 55 citations

2014 22 citations

2017 6 citations

2018 100 citations

2019 4 citations

2020 70 citations

2021 709 citations

2022 653 citations

2023 66 citations

2024 85 citations

2025 65 citations

2026 0 citations

J. Guégan

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT